CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies

Key Points

• The study aims to explore the relationship between α-Synuclein amplification and Alzheimer's biomarkers in dementia with Lewy bodies (DLB).
• Analyzed a cohort of participants clinically diagnosed with DLB.
• Investigated the association between α-Synuclein positivity and motor decline.
• Evaluated the presence of Alzheimer Disease copathology and its impact on cognitive outcomes.
• Found that α-Synuclein positivity correlates with increased motor decline.
• Identified common occurrence of AD copathology in DLB patients.
• AD copathology is associated with higher risks of cognitive and functional decline.